JPWO2021046549A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021046549A5 JPWO2021046549A5 JP2022514998A JP2022514998A JPWO2021046549A5 JP WO2021046549 A5 JPWO2021046549 A5 JP WO2021046549A5 JP 2022514998 A JP2022514998 A JP 2022514998A JP 2022514998 A JP2022514998 A JP 2022514998A JP WO2021046549 A5 JPWO2021046549 A5 JP WO2021046549A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- seq
- pharmaceutically acceptable
- conjugate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- 208000036142 Viral infection Diseases 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 10
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- JGPXDNKSIXAZEQ-SBBZOCNPSA-N (2s,3s)-3-[[5-fluoro-2-(5-fluoro-1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid Chemical group C1=C(F)C=C2C(C=3N=C(C(=CN=3)F)N[C@H]3C4CCC(CC4)[C@@H]3C(=O)O)=CNC2=N1 JGPXDNKSIXAZEQ-SBBZOCNPSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 description 1
- 229940008411 baloxavir marboxil Drugs 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229950004244 laninamivir Drugs 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 description 1
- 229960001084 peramivir Drugs 0.000 description 1
- 229950004058 pimodivir Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025065195A JP2025108559A (ja) | 2019-09-06 | 2025-04-10 | ウイルス感染症の治療のための組成物及び方法 |
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897036P | 2019-09-06 | 2019-09-06 | |
| US62/897,036 | 2019-09-06 | ||
| US201962941405P | 2019-11-27 | 2019-11-27 | |
| US62/941,405 | 2019-11-27 | ||
| US201962948143P | 2019-12-13 | 2019-12-13 | |
| US62/948,143 | 2019-12-13 | ||
| US202062959857P | 2020-01-10 | 2020-01-10 | |
| US62/959,857 | 2020-01-10 | ||
| US202062966500P | 2020-01-27 | 2020-01-27 | |
| US62/966,500 | 2020-01-27 | ||
| US202062970491P | 2020-02-05 | 2020-02-05 | |
| US62/970,491 | 2020-02-05 | ||
| US202062984705P | 2020-03-03 | 2020-03-03 | |
| US62/984,705 | 2020-03-03 | ||
| US202062988304P | 2020-03-11 | 2020-03-11 | |
| US62/988,304 | 2020-03-11 | ||
| US202063032488P | 2020-05-29 | 2020-05-29 | |
| US63/032,488 | 2020-05-29 | ||
| US202063062377P | 2020-08-06 | 2020-08-06 | |
| US63/062,377 | 2020-08-06 | ||
| PCT/US2020/049772 WO2021046549A1 (en) | 2019-09-06 | 2020-09-08 | Compositions and methods for the treatment of viral infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025065195A Division JP2025108559A (ja) | 2019-09-06 | 2025-04-10 | ウイルス感染症の治療のための組成物及び方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022546609A JP2022546609A (ja) | 2022-11-04 |
| JPWO2021046549A5 true JPWO2021046549A5 (https=) | 2023-09-15 |
| JP2022546609A5 JP2022546609A5 (https=) | 2023-09-15 |
| JP7667139B2 JP7667139B2 (ja) | 2025-04-22 |
Family
ID=74852729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514998A Active JP7667139B2 (ja) | 2019-09-06 | 2020-09-08 | ウイルス感染症の治療のための組成物及び方法 |
| JP2025065195A Pending JP2025108559A (ja) | 2019-09-06 | 2025-04-10 | ウイルス感染症の治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025065195A Pending JP2025108559A (ja) | 2019-09-06 | 2025-04-10 | ウイルス感染症の治療のための組成物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20210220478A1 (https=) |
| EP (1) | EP4025256A4 (https=) |
| JP (2) | JP7667139B2 (https=) |
| KR (1) | KR20220088527A (https=) |
| CN (2) | CN114980933B (https=) |
| AU (2) | AU2020342649B2 (https=) |
| CA (1) | CA3153359A1 (https=) |
| CL (1) | CL2022000531A1 (https=) |
| CO (1) | CO2022003078A2 (https=) |
| CR (1) | CR20220138A (https=) |
| EC (1) | ECSP22026797A (https=) |
| IL (1) | IL290792B1 (https=) |
| MX (1) | MX2022002728A (https=) |
| PE (1) | PE20221443A1 (https=) |
| PH (1) | PH12022550505A1 (https=) |
| TW (1) | TWI861205B (https=) |
| WO (1) | WO2021046549A1 (https=) |
| ZA (1) | ZA202203681B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210079278A (ko) | 2018-09-06 | 2021-06-29 | 시다라 세라퓨틱스, 인코포레이티드 | 바이러스 감염의 치료를 위한 조성물 및 방법 |
| TWI861205B (zh) | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| AU2021210987A1 (en) * | 2020-01-24 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Protein-antiviral compound conjugates |
| US20230364251A1 (en) | 2020-08-06 | 2023-11-16 | Cidara Therapeutics, Inc. | Methods for the synthesis of protein-drug conjugates |
| EP4192510A1 (en) | 2020-08-06 | 2023-06-14 | Cidara Therapeutics, Inc. | Methods for the synthesis of protein-drug conjugates |
| US20240285786A1 (en) | 2021-03-11 | 2024-08-29 | Cidara Therapeutics, Inc. | Protein-drug conjugates for antiviral therapy |
| WO2023125806A1 (zh) * | 2021-12-30 | 2023-07-06 | 苏州爱科百发生物医药技术有限公司 | 用于预防和治疗病毒感染的偶联物及其用途 |
| EP4551563A2 (en) * | 2022-07-05 | 2025-05-14 | Cidara Therapeutics, Inc. | Fc conjugates including an inhibitor of cd73 and uses thereof |
| WO2025002421A1 (zh) | 2023-06-29 | 2025-01-02 | 上海爱科百发生物医药技术股份有限公司 | 用于预防和治疗病毒感染的偶联物及其用途 |
| WO2025064869A2 (en) * | 2023-09-20 | 2025-03-27 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of cancer |
| WO2025119337A1 (zh) * | 2023-12-08 | 2025-06-12 | 苏州拓界医药有限公司 | 一种抗病毒偶联物 |
| WO2025157263A1 (zh) * | 2024-01-26 | 2025-07-31 | 浙江养生堂天然药物研究所有限公司 | 偶联物及其制备方法和用途 |
| WO2025230581A1 (en) * | 2024-05-02 | 2025-11-06 | Cidara Therapeutics, Inc. | Fc conjugates and uses thereof |
| WO2026055183A1 (en) * | 2024-09-03 | 2026-03-12 | Vir Biotechnology, Inc | Antiviral compositions and methods of using the same |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ335368A (en) | 1996-11-14 | 2001-08-31 | Biota Scient Management | Macromolecular compound with one or more neuraminidase binders, binds to the active site of influenza virus neuraminidase |
| US6495580B1 (en) | 1998-01-29 | 2002-12-17 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| AUPP913999A0 (en) | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| SG122814A1 (en) | 1999-06-28 | 2006-06-29 | Janssen Pharmaceutica Nv | Respiratory syncytial virus replication inhibitors |
| AUPR001000A0 (en) | 2000-09-08 | 2000-10-05 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| AUPR879701A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| CA2495266A1 (en) | 2002-08-09 | 2004-02-19 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| AU2006279304A1 (en) | 2005-08-19 | 2007-02-22 | Endocyte, Inc. | Multi-drug ligand conjugates |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| CN103068378B (zh) | 2010-05-10 | 2016-07-06 | 中央研究院 | 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法 |
| MA34392B1 (fr) | 2010-06-24 | 2013-07-03 | Gilead Sciences Inc | Pyrimidines en tant qu'agents antiviraux |
| RS55609B1 (sr) | 2011-04-13 | 2017-06-30 | Bristol Myers Squibb Co | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| US9834597B2 (en) | 2012-09-21 | 2017-12-05 | The Regents Of The University Of California | Modified FC polypeptides, FC conjugates, and methods of use thereof |
| BR112015008325B1 (pt) | 2012-10-16 | 2022-01-25 | Janssen Sciences Ireland Uc | Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende |
| EP3385277A1 (en) | 2013-03-15 | 2018-10-10 | F. Hoffmann-La Roche AG | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| JP6211195B2 (ja) | 2013-08-12 | 2017-10-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール |
| TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為ｒｓｖ抗病毒化合物之螺脲化合物 |
| WO2017046625A1 (en) | 2015-06-25 | 2017-03-23 | Cube Biotech Gmbh | New chelators for affinity purification of recombinant proteins |
| WO2018006063A1 (en) | 2016-07-01 | 2018-01-04 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
| US20230190950A1 (en) * | 2017-01-06 | 2023-06-22 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
| KR20210079278A (ko) * | 2018-09-06 | 2021-06-29 | 시다라 세라퓨틱스, 인코포레이티드 | 바이러스 감염의 치료를 위한 조성물 및 방법 |
| EP3982994A4 (en) | 2019-06-13 | 2023-10-04 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of respiratory syncytial virus |
| AU2020291469A1 (en) | 2019-06-13 | 2022-02-10 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| TWI861205B (zh) | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| US20240285786A1 (en) * | 2021-03-11 | 2024-08-29 | Cidara Therapeutics, Inc. | Protein-drug conjugates for antiviral therapy |
-
2020
- 2020-09-07 TW TW109130663A patent/TWI861205B/zh active
- 2020-09-08 PE PE2022000373A patent/PE20221443A1/es unknown
- 2020-09-08 MX MX2022002728A patent/MX2022002728A/es unknown
- 2020-09-08 AU AU2020342649A patent/AU2020342649B2/en active Active
- 2020-09-08 CN CN202080077368.1A patent/CN114980933B/zh active Active
- 2020-09-08 KR KR1020227011190A patent/KR20220088527A/ko active Pending
- 2020-09-08 EP EP20860243.3A patent/EP4025256A4/en active Pending
- 2020-09-08 IL IL290792A patent/IL290792B1/en unknown
- 2020-09-08 PH PH1/2022/550505A patent/PH12022550505A1/en unknown
- 2020-09-08 CA CA3153359A patent/CA3153359A1/en active Pending
- 2020-09-08 JP JP2022514998A patent/JP7667139B2/ja active Active
- 2020-09-08 CN CN202510048861.5A patent/CN120168655A/zh active Pending
- 2020-09-08 WO PCT/US2020/049772 patent/WO2021046549A1/en not_active Ceased
- 2020-09-08 CR CR20220138A patent/CR20220138A/es unknown
-
2021
- 2021-03-05 US US17/194,093 patent/US20210220478A1/en not_active Abandoned
- 2021-04-21 US US17/236,745 patent/US11510992B1/en active Active
-
2022
- 2022-03-03 CL CL2022000531A patent/CL2022000531A1/es unknown
- 2022-03-17 CO CONC2022/0003078A patent/CO2022003078A2/es unknown
- 2022-03-30 ZA ZA2022/03681A patent/ZA202203681B/en unknown
- 2022-04-05 EC ECSENADI202226797A patent/ECSP22026797A/es unknown
- 2022-08-15 US US17/887,776 patent/US12427200B2/en active Active
-
2025
- 2025-04-10 JP JP2025065195A patent/JP2025108559A/ja active Pending
- 2025-07-23 US US19/277,976 patent/US20260108618A1/en active Pending
- 2025-11-07 AU AU2025263868A patent/AU2025263868A1/en active Pending